Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
Wu, Ka Lung [1 ]
Beksac, Meral [2 ]
van Droogenbroeck, Jan [3 ]
Amadori, Sergio [4 ]
Zweegman, Sonja [5 ]
Sonneveld, Pieter [1 ]
机构：
[1] Erasmus MC, Dept Haematol, Room L-407,POB 2040, NL-3000 CA Rotterdam, Netherlands
[2] Ibni Sina Hosp, Dept Haematol, Ankara, Turkey
[3] AZ St Jan Hosp, Dept Haematol, Brugge, Belgium
[4] St Eugenio Hosp, Dept Haematol, Rome, Italy
[5] Vrije Univ Amsterdam Med Ctr, Dept Haematol, Amsterdam, Netherlands
来源：
HAEMATOLOGICA | 2006年 / 91卷 / 12期
关键词：
multiple myeloma; arsenic trioxide; single nucleotide polymorphisms;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.
引用
收藏
页码：1722 / 1723
页数：2
相关论文
共 50 条
  • [1] A phase II study of arsenic trioxide (ATO) in combination with dexamethasone (Dex) and ascorbic acid (VITC) in patients with relapsed/refractory multiple myeloma.
    Birch, R
    Schwartzberg, LS
    Lawrence, V
    Schnell, FM
    Tongol, JM
    Prill, SJ
    Smith, JM
    Henderson, IC
    [J]. BLOOD, 2003, 102 (11) : 386B - 386B
  • [2] A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma
    Berenson, James R.
    Matous, Jeffrey
    Swift, Regina A.
    Mapes, Russell
    Morrison, Blake
    Yeh, Howard S.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (06) : 1762 - 1768
  • [3] Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
    Hussein, MA
    Saleh, M
    Ravandi, F
    Mason, J
    Rifkin, RM
    Ellison, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (04) : 470 - 476
  • [4] Treatment with arsenic trioxide, ascorbic acid and dexamethasone in advanced myeloma patients: Preliminary findings of a multicenter, phase II study.
    Wu, K
    van Droogenbroeck, J
    Beksac, M
    de Knegt, Y
    Sonneveld, P
    [J]. BLOOD, 2005, 106 (11) : 367B - 367B
  • [5] A phase I/II trial evaluating the combination of arsenic trioxide, bortezomib and ascorbic acid for patients with relapsed or refractory multiple myeloma.
    Berenson, J
    Matous, J
    Ferretti, D
    Swift, R
    Mapes, R
    Morrison, B
    Yeh, H
    Bevivino, S
    [J]. BLOOD, 2005, 106 (11) : 721A - 721A
  • [6] A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myelama.
    Berenson, J. R.
    Matous, J. V.
    Ferretti, D.
    Swift, R. A.
    Mapes, R. A.
    Morrison, B.
    Yeh, H. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 449S - 449S
  • [7] A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma
    Held, Lauren A.
    Rizzieri, David
    Long, Gwynn D.
    Gockerman, Jon P.
    Diehl, Louis F.
    De Castro, Carlos M.
    Moore, Joseph O.
    Horwitz, Mitchell E.
    Chao, Nelson J.
    Gasparetto, Cristina
    [J]. CANCER INVESTIGATION, 2013, 31 (03) : 172 - 176
  • [8] A multicenter phase II study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) for patients with relapsed or refractory multiple myeloma.
    Berenson, J
    Boccia, R
    Siegel, D
    Bozdech, M
    Bessudo, A
    Stadtmauer, E
    Pomeroy, JT
    Steis, R
    Flam, M
    Lutzky, J
    Jilani, S
    Volk, J
    Lindgren, T
    Moss, R
    Patel, R
    Ferreti, D
    Yeh, H
    Bevivino, S
    [J]. BLOOD, 2005, 106 (11) : 720A - 721A
  • [9] Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma
    M J Borad
    R Swift
    J R Berenson
    [J]. Leukemia, 2005, 19 : 154 - 156
  • [10] Melphalan, arsenic trioxide and ascorbic acid (MAC) is effective in the treatment of refractory and relapsed multiple myeloma (MM).
    Borad, M
    Swift, RA
    Sadler, K
    Yang, H
    Berenson, JR
    [J]. BLOOD, 2003, 102 (11) : 235A - 236A
12345